Is transcutaneous oxygen and carbon dioxide monitoring indispensable in short- and long-term therapeutic management of non-reconstructable lower critical limb ischemia?;Il monitoraggio gasanalitico transcutaneo di O2 e CO2 nel management a breve e lungo termine dell'ischemia critica degli arti inferiori non immediatamente rivascolarizzabile

Minerva Cardioangiologica

Volumn 54, Issue 4, 2006, Pages 481-498

  Melillo, E ^a,b   Nuti, M ^a   Pedrinelli, R ^a   Buttitta, F ^a   Balbarini, A ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Carbon dioxide; Ischemia; Limb; Transcutaneous oxygen

Indexed keywords

CARBON DIOXIDE; ILOPROST; OXYGEN; PROSTANOID;

AGED; ANGIOGRAPHY; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GAS ANALYSIS; HUMAN; LIMB ISCHEMIA; LIMB SALVAGE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESSURE; RISK FACTOR; SPINAL CORD STIMULATION; SYMPTOMATOLOGY; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; BLOOD GAS MONITORING, TRANSCUTANEOUS; CRITICAL ILLNESS; FEMALE; HUMANS; ILOPROST; ISCHEMIA; LEG; MALE; MIDDLE AGED; TIME FACTORS; VASODILATOR AGENTS;

EID: 33750621990     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. European working group on critical limb ischemia: Second European consensus document on chronic leg ischemia. Eur J Vasc Surg 1992;6 Suppl A:1-32.
2. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000;31(1 Pt 2):S1-S296.
3. Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992;43:889-924.
4. Prostanoids for chronic critical leg ischaemi: a randomized, controlled, open-label trial with prostaglandin El. he ICAI Study Group. Ischemia Cronica degli Arti Inferiori. Ann Intern Med 1999;130:412-21.
5. Loosemore TM, Chalmers TC, Dormandy JA. A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Int Angiol Vol 1994;13:133-42.
6. Ubbink DT, Spincemaille GH, Reneman RS, Jacobs MJ. Prediction of imminent amputation in patients with non-reconstructible leg ischemia by means of microcirculatory investigations. J Vasc Surg 1999;30:114-21.
7. Melillo E, Catapano G, Dell'Omo G, Iabichella L, Berchiolli R, Ferrari M et al. Transcutaneous oxygen and carbon dioxide measurement in peripheral vascular disease. Vasc Surg 1995;29:273-80.
8. Melillo E, Pedrinelli R, Nuti M, Buttitta F, Giannini D, Di Stefano R et al. Can limb loss in patients with lower limb critical ischemia (CLI) be predicted by transcutaneous oxygen and carbon dioxide measurements? Int Angiol 2004;23 (1 Suppl 1):197.
9. Melillo E, Nuti M, Buttitta F, Iabichella ML, Pedrinelli R, Grossi G et al. Salvataggio d'arto farmacologico mediante iloprost nella ischemia critica degli arti inferiori non rivascolarizzabile: conferme e modifiche della nostra condotta terapeutica negli ultimi otto anni. Minerva Cardioangiol 2003;51 (1 Suppl 6):253-55.
10. Melillo E, Nuti M, Buttitta F, Balbarini A. [Medical therapy in critical lower limb ischemia when immediate revascularization is not feasible] Ital Cardiol (Rome) 2006;7:317-35. Italian.
11. Melillo E, Ferrari M, Balbarini A, Pedrinelli R. Transcutaneous gases determination in diabetic critical limb ischemia. Diabetes Care 2005;28:2081-2.
12. Blume JD. Likelihood methods for measuring statistical evidence. Statist Med 2002;21:2563-99.
13. Deeks JJ, Altman DJ. Diagnostic test4: likelihood ratios. BMJ 2004;329:168-9.
14. Bliss B, Wilkins D, Campbell WB. Treatment of limb threatening ischaemia with intravenous Iloprost: a randomised double blind placebo-controlled study. Eur J Vasc Endovasc Surg 1991;5:511-6.
15. Norgren L, Alwmark A, Angqvist KA, Heldberg B, Berqvist D, Takolander R et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb: a Scandinavian-Polish placebo-controlled randomized multicentre study. Eur J Vasc Endovasc Surg 1990;4:463-7.
16. Brock FE, Abri O, Baitsch G, Bechara G, Beck K, Corovic D et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo-controlled multicenter study with a stable prostacyclin derivative. Schweiz Med Wochenschr 1990;120:1477-82.
17. Altstaedt HO, Berzewski B, Breddin HK, Brockhaus W, Bruhn HD, Cachovan M et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukot Essent Fatty Acids 1993;49:573-8.
18. Staben P, Albring M. Treatment of patients with peripheral arterial occlusive disease Fontaine stage III and IV with intravenous iloprost: an open study in 900 patients. Prostaglandins Leukot Essent Fatty Acids 1996;54:327-33.
19. Evaluation of a conservative treatment with Iloprost in severe peripheral occlusive arterial disease (POAD). GISAP Study. Int Angiol 1994;13:70-4.
20. Pola R, Gaetani E, Flex A, Aprahamian TR, Bosch-Marce M, Losordo DW et al. Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possibile role for peroxisome proliferator-activated receptors. J Mol Cell Cardiol 2004;36:363-70.
21. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
22. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 2004;25:166-81.
23. Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003;92:711-2.
24. Schillinger M, Exner M, Mlekusch W, Amighi J, Sabeti S, Muellner M et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 2004;25:742-8.
25. Ostergren J, Sleight P, Yusuf S, anisa K, Bosch J, Qilong Y et al. HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17-24.
26. Warner GT, Perry CM. Ramipril: a review of its use in the prevention of cardiovascular outcomes. Drugs 2002;62:1381-405.
27. Labs KH, Dormandy JA, Jaeger KA, Stuerzebecher CF, Hiatt WR. Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease: clinical trial methodology. Basel PAD Clinical Trial Methodology Group. Circulation 1999;100:e75-81.
28. Duthois S, Cailleux N, Benosman B, Levesque H. Tolerance of Iloprost and results of treatment of chronic sever lower limb schaemia in diabetic patients. A retrospective study of 64 consecutive cases. Diabete Metab 2003;29:36-43.